NeuraWell strategy targeting MDD and TRD involves a new and unique combination of a broad action, highly effective existing anti-depressant with a unique molecule (NW-531) coupled with a reformulated delivery mechanism allowing the mitigation of potentially serious side effects and therapeutic compliance.
To fulfill the unmet needs in treatment-resistant anxiety, NeuraWell is targeting a neurotransmitter system known to regulate anxiety, with a unique mechanism of action that potentially can be used either as a monotherapy, or as an augmenting agent to any anti-anxiety medication.
Unique Technology to Assist in Patient Compliance
NeuraWell has developed an advanced technical patient application to assist in treatment education and side effect management. This technology is designed to help patients to understand and optimize their treatment and avoid potential serious interaction risks with other medications.